Company Description
BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors.
Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK‑targeting chimeric degradation activation compound active against wild‑type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.
It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis.
The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines Ltd. in May 2025.
BeOne Medicines Ltd. was incorporated in 2010 and is based in Basel, Switzerland.
| Country | Switzerland |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11,000 |
| CEO | John Oyler |
Contact Details
Address: Aeschengraben 27, 21st Floor Basel, 4051 Switzerland | |
| Phone | 41 61 685 19 00 |
| Website | beonemedicines.com |
Stock Details
| Ticker Symbol | ONC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001651308 |
| ISIN Number | US07725L1026 |
| Employer ID | 98-1209416 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John V. Oyler | Co-Founder, Executive Chairman and Chief Executive Officer |
| Dr. Xiaobin Wu Ph.D. | President, Chief Operating Officer and GM of China |
| Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board, Non-Executive Director and Co-Founder |
| Aaron Rosenberg | Chief Financial Officer |
| Chan Lee | General Counsel and Senior Vice President |
| Wang Lai Ph.D. | Global Head of Research & Development |
| Titus B. Ball | Vice President and Chief Accounting Officer |
| Marcello Damiani | Chief Technology Officer |
| Liza Heapes | Head of Investor Relations |
| Eleanor Duff | Senior Vice President and Head of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 18, 2025 | 144 | Filing |
| Jul 9, 2025 | 144 | Filing |
| Jul 8, 2025 | 144 | Filing |
| Jun 24, 2025 | 144 | Filing |
| Jun 23, 2025 | 144 | Filing |
| Jun 23, 2025 | 144 | Filing |
| Jun 23, 2025 | 144 | Filing |
| Jun 17, 2025 | 144 | Filing |
| Jun 17, 2025 | 144 | Filing |
| Jun 17, 2025 | 144 | Filing |